Participatory investigation of Contagious Caprine Pleuropneumonia (CCPP) in goats in the Hammer and Benna-Tsemay districts of southern Ethiopia.

The study was conducted in two selected districts of Southern Omo zones of Ethiopia, namely Hammer and Benna-Tsemay, during November 2004 and May 2005 to determine the status of contagious caprine pleuropneumonia (CCPP). Participatory disease investigation was conducted in the goat flocks owned by pastoralists of the districts. Participatory methods such as proportionate piling and matrix scoring of diseases were used to characterise major diseases of goats. Clinical and post-mortem examinations and isolation of the causative agent of CCPP were done. Serological tests were conducted using CFT. CCPP (locally termed Sompo) ranked as the first important disease of goats in the study area. Local perception of causes and signs of CCPP were described. Matrix scoring between groups revealed that disease signs and causes showed weak, moderate and good agreement by Kendall's coefficient concordance (W = 0.21-0.99). The overall sero-prevalence of CCPP was 15.5%. The causative agent was isolated from sick animals in the lab. The characteristic clinical signs, gross lesions, bacteriological isolation of the causative agent supported by participatory epidemiological disease investigation revealed that CCPP is a major disease of goats in the study districts. Participatory epidemiology using indigenous knowledge could efficiently be used to generate sufficient information with minimum cost, local materials and within reasonably short period of time, assisting the designing of feasible disease control programme in developing countries.

Inexpensive vaccines and rapid diagnostic kits tailor-made for the global eradication of rinderpest, and technology transfer to Africa and Asia.

Rinderpest is an acute and highly contagious viral disease of ruminants, often resulting in greater than 90% mortality. We previously reported the development of first- and second-generation recombinant vaccinia virus vaccines which provide complete protection against rinderpest virus (RPV) and peste-des-petits ruminants virus (PPRV). These vaccines are safe even for immunodeficient mice and macaques with acquired immunodeficiency syndrome. We developed a third-generation recombinant vaccinia virus vaccine (v2RVFH) that expresses the fusion and haemagglutinin genes of RPV under strong synthetic vaccinia virus promoters. Cattle vaccinated intramuscularly with as little as 10(3) plaque-forming units (PFU) of v2RVFH were completely protected from rinderpest. Vaccinated animals did not develop pock lesions or transmit v2RVFH to contact animals. Cattle vaccinated with a standard dose of 10(8) PFU of v2RVFH developed long-term, sterilizing immunity against rinderpest. Thus, v2RVFH is safe, efficacious, heat stable, inexpensive, easily administered, and allows serological differentiation between vaccinated and infected animals. To aid in diagnosis and differentiation of vaccinated from infected animals, we developed indirect ELISAs (iELISAs) that use baculovirus-expressed RPV or PPRV nucleoprotein as coating antigens. A single larva contains enough viral antigen to test more than 10,000 serum samples, in duplicate. African scientists trained at the ILMB successfully transferred the iELISA kit technology to more than 30 countries in Africa, providing a model for technology transfer among developing countries. Vaccination with v2RVFH, in conjunction with the iELISA kits, greatly enhances the prospects for global eradication of rinderpest, as developing nations achieve independence in control efforts.